Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant
- 6 April 2021
- journal article
- editorial
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), 273-278
- https://doi.org/10.1016/j.clcc.2021.03.002
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine ApproachMayo Clinic Proceedings, 2014
- A Case of 5-FU-Related Severe Toxicity Associated with the p.Y186C DPYD VariantClinical Pharmacology & Therapeutics, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine DosingClinical Pharmacology & Therapeutics, 2013
- Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?EPMA Journal, 2010
- Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer PatientsJournal of International Medical Research, 2010
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyJournal of Clinical Oncology, 2008
- RNA-Based 5-Fluorouracil Toxicity Requires the Pseudouridylation Activity of Cbf5pGenetics, 2008
- Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with CaucasiansClinical Cancer Research, 2006
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Fluorouracil-Induced NeurotoxicityAnnals of Pharmacotherapy, 2000